Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Autor: Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch

Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6636bc7fd14949c096b587e72af567
https://doi.org/10.1158/1535-7163.22522569.v1

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Autor: Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, Christopher McCann, Katherine McAllister, Jochen Prehn, Jamie Young, Jess Bateson, Lewis Gallagher, Magali Michaut, Vivek Iyer, Aikaterini Chatzipli, Syd Barthorpe, Daniel Ciznadija, Ido Sloma, Amy Wesa, David A. Tice, Lodewyk Wessels, Mathew Garnett, Daniel B. Longley, Ultan McDermott, Simon S. McDade

Publikováno v: Grinkevich, V, Wappett, M, Crawford, N, Price, S, Lees, A, McCann, C, McAllister, K A, Prehn, J H, Young, J, Bateson, J H, Gallagher, L, Michaut, M, Iyer, V, Chatzipli, A, Barthorpe, S, Ciznadija, D, Sloma, I, Wesa, A, Tice, D A, Wessels, L F A, Garnet, M, Longley, D B, McDermott, U & McDade, S S 2022, ' Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists ', Molecular Cancer Therapeutics, vol. 21, no. 4, pp. 594-606 . https://doi.org/10.1158/1535-7163.MCT-21-0532
Molecular Cancer Therapeutics, 21(4)

Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2ab26abf156cbc95c25811c72ca2545
http://resolver.tudelft.nl/uuid:c0a9df57-b127-4fa9-aaf2-3cdcc5dca58b